CoenzymeQ10
Phase 3Small molecule
CoenzymeQ10 is one of 37 small molecule programs targeting Pneumonia. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1CoenzymeQ10
TTanta University
Phase 3
Innohep
Alnylam PharmaceuticalsPreclinical
Prevacid
TakedaPreclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Zantac 150
CChattem
Preclinical
Pepcid
KKenvue Brands
Preclinical
Mucinex
AAultman Health Foundation
Preclinical
Cancidas
FFresenius Kabi Oncology Ltd.
Preclinical
Tagamet
DDT MedTech, LLC
Preclinical
Piperacillin/tazobactam
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CoenzymeQ10. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTanta University